THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 19/Aug 13:44
FDA approves new therapy for glioma patients for first time in decades
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global phase 3, double-blinded, randomised clinical trial, vorasidenib more than doubled progression-free survival and delayed the need for treatment with radiation and chemotherapy for patients with Grade 2 [...]
Articles similaires
Elle Macpherson refused chemotherapy to treat breast cancer despite advice from 32 doctors
smh.com.au - 03/Sep 23:43
Doctors advised the model to undergo a mastectomy with radiation, chemotherapy, hormone therapy and a breast reconstruction.
First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
drugs.com - 09/Sep 20:09
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
zacks.com - 28/Aug 17:03
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
Elle Macpherson refused chemotherapy to treat breast cancer despite advice from 32 doctors
smh.com.au - 04/Sep 06:22
Following surgery, doctors advised the model to undergo a mastectomy with radiation, chemotherapy and a breast reconstruction.
First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
drugs.com - 05/Sep 04:09
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Relay Therapeutics reports positive interim data for RLY─2608 demonstrating clinically meaningful progression free survival
pharmabiz.com - 10/Sep 00:00
Relay Therapeutics, Inc., a clinical─stage precision medicine company transforming the drug discovery process by combining leading─edge...
Early trial results leave Imugene patients cancer-free
thewest.com.au - 02/Sep 07:23
The first two blood cancer patients in a US-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120...
Managing mucositis, a side effect in breast cancer treatment
times of india - 09/Sep 04:37
Breast cancer is the leading cancer among Indian women, especially in urban regions due to lifestyle shifts. Early detection challenges contribute to...
Gene Therapy Restores Vision for Patients Born Blind
medindia.net - 08/Sep 12:37
Patients born with genetic blindness experienced significant visual improvements after a single treatment with gene therapy developed at the...
Les derniers communiqués
-
Aucun élément